Cover Image
市場調查報告書

疼痛管理的藥理學性治療和設備的治療:美國市場

U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

出版商 Medtech Insight 商品編碼 204529
出版日期 內容資訊 英文 192 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疼痛管理的藥理學性治療和設備的治療:美國市場 U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
出版日期: 2014年06月01日 內容資訊: 英文 192 Pages
簡介

美國的疼痛管理產品的整體市場,從2013年的364億美元擴大到2018年的447億美元。整體銷售額中,醫藥品佔92%以上,剩下8%為疼痛管理設備。

本報告提供美國疼痛管理的醫藥品及設備的市場相關調查、疼痛的各種類型、臨床方法種類與概要、美國的得病率、醫藥品及設備的市場成長預測(各藥物、設備類型)、供應商的市場佔有率,以及主要企業的簡介等彙整。

摘要整理

第1章 疼痛管理概要

  • 疼痛的生理學
    • 神經系統
    • 疼痛的認識
    • 疼痛分類
  • 疼痛評估技術
  • 得病率
  • 一般的疼痛症候群
    • 關節炎性疼痛
    • 背痛
    • 燙傷疼痛
    • 癌症性疼痛
    • 頭痛
    • HIV、愛滋病性疼痛
    • 陣痛
    • 坐骨神經痛
    • 下巴關節疼痛
    • 外傷性疼痛等
  • 臨床方法
    • 疼痛管理指南
    • 年長者疼痛管理指南
    • 介入性疼痛管理指南
    • 疼痛管理的選項

第2章 疼痛管理醫藥品

  • 醫藥品的製劑和藥物遞輸
    • 口服給藥
    • 注射、注射
    • 吸入
    • 經皮
    • 經粘膜
    • 非類固醇消炎藥
  • 阿斯匹林的優點
    • 心臟病發作/預防中風
    • 心臟衰竭
    • 預防癌症
  • 市場分析
    • 非處方止痛藥/麻醉劑
    • 非處方局部用止痛藥/麻醉劑
    • 處方止痛藥/麻醉劑
    • 市場預測

第3章 疼痛管理設備

  • 電刺激
  • 止痛藥注射泵
  • 市場預測

第4章 企業簡介

  • AstraZeneca PLC
  • Baxter Healthcare, Inc./Baxter International, Inc.
  • Bayer HealthCare AG/Bayer AG
  • Boston Scientific Corporation
  • CareFusion Corporation
  • Chattem, Inc./sanofi-aventis LLC
  • DJO Global, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceutical Holdings, Inc./Endo International PLC
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • International Rehabilitative Sciences, Inc., d/b/a RS Medical
  • Johnson & Johnson
  • Medtronic, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Teva Pharmaceutical Industries LTD

企業清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: A374

Pain is the single most common reason patients seek medical care, accounting for approximately half of all physician office visits in the United States (U.S.); some studies suggest that more than one-third of people in the U.S. suffer from a chronic pain condition at some point in their lives.

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).

During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.

Table of Contents

EXECUTIVE SUMMARY

  • i. Pain Management Pharmaceuticals
    • a. Nonprescription Analgesics and Anesthetics
      • i. Nonprescription Systemic Analgesics
      • ii. Nonprescription Topical Analgesics
      • iii. Market Forecast
    • b. Prescription Analgesics and Anesthetics
      • i. Prescription Non-Steroidal Anti-Inflammatory Drugs
      • ii. Opioid Analgesics
      • iii. Opioid/Nonopioid Combination Analgesics
      • iv. Antimigraine Analgesics
      • v. Adjuvant Analgesics
      • vi. General, Regional, and Local Anesthetics
      • vii.. Market Forecast
    • c. Combined Market Forecast
      • ii. Pain Management Devices
    • a. Electrical Stimulators
      • i. Transcutaneous Electrical Nerve Stimulators
      • ii. Neurostimulators
      • iii. Market Forecast
    • b. Analgesia Infusion Pumps
      • i. Implantable Analgesia Infusion Pumps
      • ii. External Analgesia Infusion Pumps
      • iii. Market Forecast
    • c. Combined Market Forecast
      • iii. Combined Market Forecast
  • Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018

1. PAIN MANAGEMENT OVERVIEW

  • 1.1. Pain Physiology
    • 1.1.1. The Nervous System
    • 1.1.2. Pain Perception
    • 1.1.3. Pain Classification
      • 1.1.3.1. Nociceptive Pain
      • 1.1.3.2. Non-Nociceptive Pain
      • 1.1.3.3. Acute Pain
      • 1.1.3.4. Chronic Pain
  • 1.2. Pain Assessment Techniques
  • 1.3. Pain Prevalence
  • 1.4. Common Pain Syndromes
    • 1.4.1. Arthritis Pain
    • 1.4.2. Back Pain
    • 1.4.3. Burn Pain
    • 1.4.4. Cancer Pain
    • 1.4.5. Headache Pain
    • 1.4.6. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain
    • 1.4.7. Obstetric Pain
    • 1.4.8. Podiatric Pain
    • 1.4.9. Sciatic Pain
    • 1.4.10. Temporomandibular Pain
    • 1.4.11. Trauma Pain
  • 1.5. Clinical Approaches to Pain Management
    • 1.5.1. Pain Management Guidelines
    • 1.5.2. Pain Management Guidelines for Older Adults
    • 1.5.3. Interventional Pain Management Guidelines
    • 1.5.4. Pain Management Options
      • 1.5.4.1. Pharmaceutical Options
      • 1.5.4.2. Device-Based Options
      • 1.5.4.3. Alternative Therapy Options
  • Exhibit 1-1: Common Causes of Neuropathic Pain
  • Exhibit 1-2: United States Population, by Selected Ages, 1990-2050
  • Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management

2. PAIN MANAGEMENT PHARMACEUTICALS

  • 2.1. Pharmaceutical Formulations and Drug Delivery
    • 2.1.1. Oral Drug Delivery
    • 2.1.2. Injection/Infusion Drug Delivery
      • 2.1.2.1. Injection
        • 2.1.2.1.1. Intramuscular Injection
        • 2.1.2.1.2. Subcutaneous Injection
      • 2.1.2.2. Infusion
        • 2.1.2.2.1. Intravenous Infusion
        • 2.1.2.2.2. Intraspinal Infusion
        • 2.1.2.2.3. Intraoperative Site Infusion
    • 2.1.3. Inhalation Drug Delivery
    • 2.1.4. Transdermal Drug Delivery
    • 2.1.5. Transmucosal Drug Delivery
    • 2.1.6. Nonsteroidal Anti-Inflammatory Drugs
      • 2.1.6.1. Heart Attack and Hypertension Risks
      • 2.1.6.2. The Food and Drug Administration and Labeling
      • 2.1.6.3. Naproxen Risks
  • 2.2. The Benefits of Aspirin
    • 2.2.1. Aspirin and Heart Attack/Stroke Prevention
    • 2.2.2. Aspirin and Heart Failure
    • 2.2.3. Aspirin and Cancer Prevention
  • 2.3. Market Analysis
    • 2.3.1. Nonprescription Analgesics and Anesthetics
      • 2.3.1.1. Market Forecast
      • 2.3.1.2. Nonprescription Systemic Analgesics
        • 2.3.1.2.1. Acetaminophen
        • 2.3.1.2.2. Nonprescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.1.2.3. Market Forecast
        • 2.3.1.2.4. Competitive Analysis
    • 2.3.1.3. Nonprescription Topical Analgesics and Anesthetics
      • 2.3.1.3.1. Amino Amides and Esters
      • 2.3.1.3.2. Capsaicin
      • 2.3.1.3.3. Methyl and Trolamine Salicylates
      • 2.3.1.3.4. Topical Patches
      • 2.3.1.3.5. Market Forecast
      • 2.3.1.3.6. Competitive Analysis
    • 2.3.2. Prescription Analgesics and Anesthetics
      • 2.3.2.1. Market Forecast
      • 2.3.2.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.2.2.1. Acetic Acid Derivatives
        • 2.3.2.2.2. Anthranilic Acid Derivatives
        • 2.3.2.2.3. Cyclooxygenase-2 Selective Inhibitors
        • 2.3.2.2.4. Enolic Acid Derivatives
        • 2.3.2.2.5. Propionic Acid Derivatives
        • 2.3.2.2.6. Salicylic Acid Derivatives
        • 2.3.2.2.7. Market Forecast
        • 2.3.2.2.8. Competitive Analysis
      • 2.3.2.3. Opioid Analgesics
        • 2.3.2.3.1. Buprenorphine
        • 2.3.2.3.2. Butorphanol
        • 2.3.2.3.3. Codeine
        • 2.3.2.3.4. Fentanyl
        • 2.3.2.3.5. Hydromorphone
        • 2.3.2.3.6. Levorphanol
        • 2.3.2.3.7. Meperidine
        • 2.3.2.3.8. Morphine
        • 2.3.2.3.9. Nalbuphine
        • 2.3.2.3.10. Oxycodone
        • 2.3.2.3.11. Oxymorphone
        • 2.3.2.3.12. Pentazocine
        • 2.3.2.3.13. Propoxyphene
        • 2.3.2.3.14. Remifentanil
        • 2.3.2.3.15. Tramadol
        • 2.3.2.3.16. Tapentadol
        • 2.3.2.3.17. Hydrocodone
        • 2.3.2.3.18. Market Forecast
        • 2.3.2.3.19. Competitive Analysis
      • 2.3.2.4. Opioid/Nonopioid Combination Analgesics
        • 2.3.2.4.1. Market Forecast
        • 2.3.2.4.2. Competitive Analysis
      • 2.3.2.5. Antimigraine Analgesics
        • 2.3.2.5.1. Diclofenac
        • 2.3.2.5.2. Dihydroergotamine
        • 2.3.2.5.3. Divalproex Sodium
        • 2.3.2.5.4. Triptans
        • 2.3.2.5.5. Market Forecast
        • 2.3.2.5.6. Competitive Analysis
      • 2.3.2.6. Adjuvant Analgesics
        • 2.3.2.6.1. Anticonvulsants
        • 2.3.2.6.2. Antidepressants
        • 2.3.2.6.3. Corticosteriods
        • 2.3.2.6.4. Market Forecast
        • 2.3.2.6.5. Competitive Analysis
      • 2.3.2.7. General, Regional, and Local Anesthetics
        • 2.3.2.7.1. Inhalation General Anesthetics
        • 2.3.2.7.2. Intravenous General Anesthetics
        • 2.3.2.7.3. Anesthetics Used in Balanced Anesthesia
        • 2.3.2.7.4. Regional/Local Anesthetics
        • 2.3.2.7.5. Market Forecast
        • 2.3.2.7.6. Competitive Analysis
    • 2.3.3. Combined Market Forecast
  • Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods
  • Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics
  • Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics
  • Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018
  • Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier
  • Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier
  • Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018
  • Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier
  • Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier
  • Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier
  • Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier
  • Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier
  • Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018

3. PAIN MANAGEMENT DEVICES

  • 3.1. Electrical Stimulators
    • 3.1.1. Transcutaneous Electrical Nerve Stimulators
      • 3.1.1.1. Market Forecast
      • 3.1.1.2. Competitive Analysis
    • 3.1.2. Neurostimulators
      • 3.1.2.1. Occipital Nerve Stimulation
      • 3.1.2.2. Neuromuscular Stimulators
      • 3.1.2.3. Spinal Cord and Peripheral Nerve Stimulators
      • 3.1.2.4. Market Forecast
      • 3.1.2.6. Competitive Analysis
  • 3.2. Analgesia Infusion Pumps
    • 3.2.1. Implantable Analgesia Infusion Pumps
      • 3.2.1.1. Market Forecast
      • 3.2.1.2. Competitive Analysis
    • 3.2.2. External Analgesia Infusion Pumps
      • 3.2.2.1. Nerve Block
      • 3.2.2.2. Patient-Controlled Analgesia Infusion Pumps
      • 3.2.2.3. Products
      • 3.2.2.4. Market Forecast
      • 3.2.2.5. Competitive Analysis
  • 3.3. Combined Market Forecast
  • Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder
  • Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy
  • Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018
  • Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
  • Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018
  • Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier
  • Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier
  • Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018

4. COMPANY PROFILES

  • 4.1. AstraZeneca PLC
  • 4.2. Baxter Healthcare, Inc./Baxter International, Inc.
  • 4.3. Bayer HealthCare AG/Bayer AG
  • 4.4. Boston Scientific Corporation
  • 4.5. CareFusion Corporation
  • 4.6. Chattem, Inc./sanofi-aventis LLC
  • 4.7. DJO Global, Inc.
  • 4.8. Eli Lilly and Company
  • 4.9. Endo Pharmaceutical Holdings, Inc./Endo International PLC
  • 4.10. GlaxoSmithKline PLC
  • 4.11. Hospira, Inc.
  • 4.12. International Rehabilitative Sciences, Inc., d/b/a RS Medical
  • 4.13. Johnson & Johnson
  • 4.14. Medtronic, Inc.
  • 4.15. Pfizer, Inc.
  • 4.16. Purdue Pharma LP
  • 4.17. Teva Pharmaceutical Industries LTD

APPENDIX: COMPANY LISTING

Back to Top